{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:56:14Z","timestamp":1772801774906,"version":"3.50.1"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ejim.2019.11.017","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T05:40:18Z","timestamp":1575265218000},"page":"15-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Proton pump inhibitors and cardiovascular adverse effects: Real or surreal worries?"],"prefix":"10.1016","volume":"72","author":[{"given":"Antonis A.","family":"Manolis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodora A.","family":"Manolis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Melita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niki","family":"Katsiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0336-4745","authenticated-orcid":false,"given":"Antonis S.","family":"Manolis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2019.11.017_bib0001","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/689531","article-title":"Brand name and generic proton pump inhibitor prescriptions in the United States: insights from the national ambulatory medical care survey (2006\u20132010)","volume":"2015","author":"Gawron","year":"2015","journal-title":"Gastroenterol Res Pract"},{"key":"10.1016\/j.ejim.2019.11.017_bib0002","doi-asserted-by":"crossref","first-page":"101","DOI":"10.7326\/0003-4819-152-2-201001190-00009","article-title":"International consensus recommendations on the management of patients with non-variceal upper gastrointestinal bleeding","volume":"152","author":"Barkun","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2019.11.017_bib0003","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.jacc.2008.08.002","article-title":"ACCF\/ACG\/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and nsaid use: a report of the American college of cardiology foundation task force on clinical expert consensus documents","volume":"52","author":"Bhatt","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2019.11.017_bib0004","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1586\/17512433.2013.811206","article-title":"Perils and pitfalls of long-term effects of proton pump inhibitors","volume":"6","author":"Wilhelm","year":"2013","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.ejim.2019.11.017_bib0005","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.hlc.2017.10.020","article-title":"Proton pump inhibitors and cardiovascular events: a systematic review","volume":"27","author":"Shiraev","year":"2018","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.ejim.2019.11.017_bib0006","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1093\/eurheartj\/ehz104","article-title":"Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction","volume":"40","author":"Sehested","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2019.11.017_bib0007","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.tcm.2018.10.008","article-title":"Cardiovascular and non-cardiovascular concerns with proton pump inhibitors: are they safe","volume":"29","author":"Corsonello","year":"2018","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.ejim.2019.11.017_bib0008","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ijcard.2014.09.036","article-title":"Proton pump inhibitor use represents an independent risk factor for myocardial infarction","volume":"177","author":"Shih","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2019.11.017_bib0009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124653","article-title":"Proton pump inhibitor usage and the risk of myocardial infarction in the general population","volume":"10","author":"Shah","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejim.2019.11.017_bib0010","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-015735","article-title":"Risk of death among users of proton pump inhibitors: a longitudinal observational cohort study of united states veterans","volume":"7","author":"Xie","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejim.2019.11.017_bib0011","doi-asserted-by":"crossref","first-page":"l1580","DOI":"10.1136\/bmj.l1580","article-title":"Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among us veterans: cohort study","volume":"365","author":"Xie","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2019.11.017_bib0012","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/joim.12698","article-title":"Long-term use of proton pump inhibitors, dose-response relationship and associated risk of ischemic stroke and myocardial infarction","volume":"283","author":"Sehested","year":"2018","journal-title":"J Intern Med"},{"key":"10.1016\/j.ejim.2019.11.017_bib0013","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.atherosclerosis.2018.08.035","article-title":"Use of proton pump inhibitors and risk of ischemic events in the general population","volume":"277","author":"Casula","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejim.2019.11.017_bib0014","doi-asserted-by":"crossref","first-page":"e12926","DOI":"10.1111\/nmo.12926","article-title":"Proton pump inhibitor monotherapy and the risk of cardiovascular events in patients with gastro-esophageal reflux disease: a meta-analysis","volume":"29","author":"Sun","year":"2017","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.ejim.2019.11.017_bib0015","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1536\/ihj.18-584","article-title":"Real-World relationship between proton pump inhibitors and cerebro-cardiovascular outcomes independent of clopidogrel","volume":"60","author":"Li","year":"2019","journal-title":"Int Heart J"},{"key":"10.1016\/j.ejim.2019.11.017_bib0016","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/apt.14955","article-title":"Systematic review with meta-analysis: risk of adverse cardiovascular events with proton pump inhibitors independent of clopidogrel","volume":"48","author":"Batchelor","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejim.2019.11.017_bib0017","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/14779072.2019.1615446","article-title":"Proton pump inhibitor-induced hypomagnesemia complicated with serious cardiac arrhythmias","volume":"17","author":"Chrysant","year":"2019","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.ejim.2019.11.017_bib0018","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3109\/0886022X.2015.1057800","article-title":"Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies","volume":"37","author":"Cheungpasitporn","year":"2015","journal-title":"Ren Fail"},{"key":"10.1016\/j.ejim.2019.11.017_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112558","article-title":"The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis","volume":"9","author":"Park","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejim.2019.11.017_bib0020","doi-asserted-by":"crossref","first-page":"e15011","DOI":"10.1097\/MD.0000000000015011","article-title":"Does the use of proton pump inhibitors increase the risk of hypomagnesemia: an updated systematic review and meta-analysis","volume":"98","author":"Liao","year":"2019","journal-title":"Med (Baltim)"},{"key":"10.1016\/j.ejim.2019.11.017_bib0021","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/MOG.0b013e32833ff5d6","article-title":"Proton pump inhibitors and severe hypomagnesaemia","volume":"27","author":"Cundy","year":"2011","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.ejim.2019.11.017_bib0022","unstructured":"FDA.FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs). 2011 https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-low-magnesium-levels-can-be-associated-long-term-use-proton-pump (accessed on July 30, 2019)."},{"key":"10.1016\/j.ejim.2019.11.017_bib0023","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/ehjcvp\/pvy030","article-title":"Trends in cardiovascular and bleeding outcomes in acute coronary syndrome patients treated with or without proton pump inhibitors during the introduction of novel P2Y12 inhibitors: a five-year experience from a single-centre observational registry","volume":"5","author":"Hoedemaker","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.ejim.2019.11.017_bib0024","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/heartjnl-2012-301632","article-title":"Lower gi bleeding is more common than upper among patients on dual antiplatelet therapy: long-term follow-up of a cohort of patients commonly using ppi co-therapy","volume":"98","author":"Casado Arroyo","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.ejim.2019.11.017_bib0025","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1503\/cmaj.082001","article-title":"A population-based study of the drug interaction between proton pump inhibitors and clopidogrel","volume":"180","author":"Juurlink","year":"2009","journal-title":"CMAJ"},{"key":"10.1016\/j.ejim.2019.11.017_bib0026","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2019.11.017_bib0027","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijcard.2012.03.085","article-title":"No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis","volume":"167","author":"Kwok","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2019.11.017_bib0028","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12872-016-0453-6","article-title":"Is the concomitant use of clopidogrel and proton pump inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty? A systematic review and meta-analysis of recently published studies (2012 - 2016)","volume":"17","author":"Bundhun","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.ejim.2019.11.017_bib0029","doi-asserted-by":"crossref","first-page":"e9638","DOI":"10.1097\/MD.0000000000009638","article-title":"Influence of proton pump inhibitors on clinical outcomes in coronary heart disease patients receiving aspirin and clopidogrel: a meta-analysis","volume":"97","author":"Hu","year":"2018","journal-title":"Med (Baltim)"},{"key":"10.1016\/j.ejim.2019.11.017_bib0030","article-title":"Efficacy and safety of clopidogrel only vs. clopidogrel added proton pump inhibitors in the treatment of patients with coronary heart disease after percutaneous coronary intervention: a systematic review and meta-analysis","volume":"23","author":"Pang","year":"2019","journal-title":"Int J Cardiol Heart Vasc"},{"key":"10.1016\/j.ejim.2019.11.017_bib0031","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3389\/fphys.2018.01550","article-title":"PPIs are not responsible for elevating cardiovascular risk in patients on clopidogrel-a systematic review and meta-analysis","volume":"9","author":"Demcsak","year":"2018","journal-title":"Front Physiol"},{"key":"10.1016\/j.ejim.2019.11.017_bib0032","doi-asserted-by":"crossref","first-page":"378","DOI":"10.7326\/0003-4819-153-6-201009210-00005","article-title":"Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study","volume":"153","author":"Charlot","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2019.11.017_bib0033","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/hrt.2009.181107","article-title":"The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease","volume":"96","author":"Wurtz","year":"2010","journal-title":"Heart"},{"key":"10.1016\/j.ejim.2019.11.017_bib0034","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1161\/CIRCULATIONAHA.111.032912","article-title":"Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial","volume":"125","author":"Goodman","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2019.11.017_bib0035","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/STROKEAHA.117.019166","article-title":"Cerebrovascular outcomes with proton pump inhibitors and thienopyridines: a systematic review and meta-analysis","volume":"49","author":"Malhotra","year":"2018","journal-title":"Stroke"},{"key":"10.1016\/j.ejim.2019.11.017_bib0036","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ahj.2015.05.017","volume":"170","author":"Nicolau","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.ejim.2019.11.017_bib0037","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.4103\/0366-6999.220304","article-title":"Impact of proton-pump inhibitors on the pharmacodynamic effect and clinical outcomes in patients receiving dual antiplatelet therapy after percutaneous coronary intervention: a propensity score analysis","volume":"130","author":"Zhu","year":"2017","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.ejim.2019.11.017_bib0038","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/MEG.0000000000001125","article-title":"Reduction in postpercutaneous coronary intervention angina in addition to gastrointestinal events in patients on combined proton pump inhibitors and dual antiplatelet therapy: a systematic review and meta-analysis","volume":"30","author":"Khan","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"19","key":"10.1016\/j.ejim.2019.11.017_bib0039","article-title":"Meta-analysis of efficacy and safety of proton pump inhibitors with dual antiplatelet therapy for coronary artery disease","author":"Khan","year":"2019","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.ejim.2019.11.017_bib0040","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1161\/CIRCOUTCOMES.114.001177","article-title":"Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review","volume":"8","author":"Melloni","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ejim.2019.11.017_bib0041","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1053\/j.gastro.2017.12.006","article-title":"No significant association between proton pump inhibitor use and risk of stroke after adjustment for lifestyle factors and indication","volume":"154","author":"Nguyen","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2019.11.017_bib0042","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.therap.2017.08.003","article-title":"Chronic use of proton pump inhibitors, adverse events and potential biological mechanisms: a translational analysis","volume":"73","author":"Kheloufi","year":"2018","journal-title":"Therapie"},{"key":"10.1016\/j.ejim.2019.11.017_bib0043","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1161\/CIRCRESAHA.116.308807","article-title":"Proton pump inhibitors accelerate endothelial senescence","volume":"118","author":"Yepuri","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.ejim.2019.11.017_bib0044","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/00004872-200502000-00001","article-title":"Endothelial function and dysfunction. part II: association with cardiovascular risk factors and diseases. a statement by the working group on Endothelins and endothelial factors of the European society of hypertension","volume":"23","author":"Brunner","year":"2005","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2019.11.017_bib0045","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10522-016-9675-3","article-title":"Different transcriptional profiling between senescent and non-senescent human coronary artery endothelial cells (HCAECs) by omeprazole and lansoprazole treatment","volume":"18","author":"Costarelli","year":"2017","journal-title":"Biogerontology"},{"key":"10.1016\/j.ejim.2019.11.017_bib0046","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1161\/CIRCULATIONAHA.113.003602","article-title":"Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine","volume":"128","author":"Ghebremariam","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2019.11.017_bib0047","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1161\/01.CIR.0000085067.55901.89","article-title":"Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine","volume":"108","author":"Stuhlinger","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2019.11.017_bib0048","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1161\/01.ATV.0000219615.88323.b4","article-title":"Dimethylarginine dimethylaminohydrolase 2 increases vascular endothelial growth factor expression through Sp1 transcription factor in endothelial cells","volume":"26","author":"Hasegawa","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ejim.2019.11.017_bib0049","first-page":"165","article-title":"Blockade of cardiac proton pump impairs ventricular remodeling through a superoxide-DDAH-dependent pathway in infarcted rats","volume":"35","author":"Chen","year":"2019","journal-title":"Acta Cardiol Sin"},{"key":"10.1016\/j.ejim.2019.11.017_bib0050","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.freeradbiomed.2012.06.001","article-title":"Increase in gastric pH reduces hypotensive effect of oral sodium nitrite in rats","volume":"53","author":"Pinheiro","year":"2012","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.ejim.2019.11.017_bib0051","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.niox.2019.01.015","article-title":"Mechanisms impairing blood pressure responses to nitrite and nitrate","volume":"85","author":"Oliveira-Paula","year":"2019","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.ejim.2019.11.017_bib0052","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.freeradbiomed.2015.06.038","article-title":"Gastric S-nitrosothiol formation drives the antihypertensive effects of oral sodium nitrite and nitrate in a rat model of renovascular hypertension","volume":"87","author":"Pinheiro","year":"2015","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.ejim.2019.11.017_bib0053","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1530\/eje.0.1500299","article-title":"Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin a levels in man","volume":"150","author":"Giusti","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ejim.2019.11.017_bib0054","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2217\/bmm.13.102","article-title":"Chromogranin a as a biomarker in cardiovascular disease","volume":"8","author":"Goetze","year":"2014","journal-title":"Biomark Med"},{"key":"10.1016\/j.ejim.2019.11.017_bib0055","unstructured":"European Medicines Agency. Pharmacovigilance risk assessment committee (PRAC) recommendations on signals. http:\/\/wwwemaeuropaeu\/docs\/en_GB\/document_library\/PRAC_recommendation_on_signal\/2016 2016 (Accessed 30 July 2019):1\u20138."},{"key":"10.1016\/j.ejim.2019.11.017_bib0056","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.tcm.2018.11.006","article-title":"Editorial commentary: pathophysiological effects of proton pump inhibitors in cardiac patients: time for a critical reappraisal","volume":"29","author":"Fragasso","year":"2019","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.ejim.2019.11.017_bib0057","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1530\/EC-14-0027","article-title":"Biological function and clinical relevance of chromogranin a and derived peptides","volume":"3","author":"D'Amico M","year":"2014","journal-title":"Endocr Connect"},{"key":"10.1016\/j.ejim.2019.11.017_bib0058","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1161\/CIRCRESAHA.110.219493","article-title":"The neuropeptide catestatin acts as a novel angiogenic cytokine via a basic fibroblast growth factor-dependent mechanism","volume":"107","author":"Theurl","year":"2010","journal-title":"Circ Res"},{"key":"10.1016\/j.ejim.2019.11.017_bib0059","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1681\/ASN.2008111148","article-title":"Chromogranin a regulates renal function by triggering weibel-palade body exocytosis","volume":"20","author":"Chen","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2019.11.017_bib0060","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41569-019-0176-3","article-title":"Endothelins in cardiovascular biology and therapeutics","volume":"16","author":"Dhaun","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.ejim.2019.11.017_bib0061","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.cardiores.2007.06.004","article-title":"The importance of endothelin-1 for vascular dysfunction in cardiovascular disease","volume":"76","author":"Bohm","year":"2007","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ejim.2019.11.017_bib0062","doi-asserted-by":"crossref","first-page":"11235","DOI":"10.1096\/fj.201900839R","article-title":"Low gut microbiota diversity and dietary magnesium intake are associated with the development of PPI-induced hypomagnesemia","volume":"33","author":"Gommers","year":"2019","journal-title":"FASEB J."},{"key":"10.1016\/j.ejim.2019.11.017_bib0063","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1161\/CIRCRESAHA.116.309157","article-title":"Letter by marlicz et\u00a0al. regarding article, \"Proton pump inhibitors accelerate endothelial senescence","volume":"119","author":"Marlicz","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.ejim.2019.11.017_bib0064","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0735-1097(99)00448-9","article-title":"Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the bruneck study","volume":"34","author":"Wiedermann","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2019.11.017_bib0065","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/dmd.32.8.821","article-title":"Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities","volume":"32","author":"Li","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ejim.2019.11.017_bib0066","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jacc.2009.12.071","article-title":"Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19\u00d72 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis","volume":"56","author":"Hulot","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2019.11.017_bib0067","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1177\/1074248416663647","article-title":"Combination use of clopidogrel and proton pump inhibitors increases major adverse cardiovascular events in patients with coronary artery disease: a meta-analysis","volume":"22","author":"Niu","year":"2017","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.ejim.2019.11.017_bib0068","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.jacc.2010.03.100","article-title":"Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the plato (PLATelet inhibition and patient outcomes) platelet substudy","volume":"56","author":"Storey","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2019.11.017_bib0069","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1093\/eurheartj\/eht042","article-title":"Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy","volume":"34","author":"Agewall","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2019.11.017_bib0070","unstructured":"FDA. Federal Food, Drug, and Cosmetic Act (FDCA) for Plavix (clopidogrel bisulfate). 2016. Reference ID: 3986952. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/...\/020839Orig1s062,s064ltr.pdf. (Accessed July 30 2019,)."},{"key":"10.1016\/j.ejim.2019.11.017_bib0071","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1365-2141.2011.08633.x","article-title":"Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment","volume":"153","author":"Teichert","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2019.11.017_bib0072","doi-asserted-by":"crossref","unstructured":"Bertram V., Yeo K., Anoopkumar-Dukie S., Bernaitis N. Proton pump inhibitors co-prescribed with warfarin reduce warfarin control as measured by time in therapeutic range. Int J Clin Pract2019:e13382.","DOI":"10.1111\/ijcp.13382"},{"key":"10.1016\/j.ejim.2019.11.017_bib0073","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1053\/j.gastro.2016.08.054","article-title":"Association of proton pump inhibitors with reduced risk of warfarin-related serious upper gastrointestinal bleeding","volume":"151","author":"Ray","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2019.11.017_bib0074","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/pds.3881","article-title":"The potential drug-drug interaction between proton pump inhibitors and warfarin","volume":"24","author":"Henriksen","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ejim.2019.11.017_bib0075","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1160\/TH11-10-0718","article-title":"Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice","volume":"107","author":"Huisman","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2019.11.017_bib0076","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.joa.2017.07.013","article-title":"Influence of proton pump inhibitors on blood dabigatran concentrations in japanese patients with non-valvular atrial fibrillation","volume":"33","author":"Kuwayama","year":"2017","journal-title":"J Arrhythm"},{"key":"10.1016\/j.ejim.2019.11.017_bib0077","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1001\/jama.2018.17242","article-title":"Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding","volume":"320","author":"Ray","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2019.11.017_bib0078","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002095.pub5","article-title":"Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease","author":"Sigterman","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejim.2019.11.017_bib0079","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000489165","article-title":"H2 receptor antagonists versus proton pump inhibitors in patients on dual antiplatelet therapy for coronary artery disease: a systematic review","volume":"140","author":"Almufleh","year":"2018","journal-title":"Cardiology"},{"issue":"5","key":"10.1016\/j.ejim.2019.11.017_bib0080","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005110","article-title":"Associations of acid suppressive therapy with cardiac mortality in heart failure patients","volume":"6","author":"Yoshihisa","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ejim.2019.11.017_bib0081","doi-asserted-by":"crossref","first-page":"e0409","DOI":"10.1097\/MD.0000000000010409","article-title":"Cardioprotective effect of histamine H2 antagonists in congestive heart failure: a systematic review and meta-analysis","volume":"97","author":"Zhang","year":"2018","journal-title":"Med (Baltim)"},{"issue":"Suppl 2","key":"10.1016\/j.ejim.2019.11.017_bib0082","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2036.1993.tb00597.x","article-title":"Safety issues relating to long-term treatment with histamine H2-receptor antagonists","volume":"7","author":"Sabesin","year":"1993","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejim.2019.11.017_bib0083","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1161\/CIR.0b013e318202f701","volume":"122","author":"Abraham","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2019.11.017_bib0084","first-page":"92","article-title":"Proton pump inhibitors receiving and prognosis of patients after scheduled percutaneous coronary interventions","volume":"90","author":"Komarov","year":"2018","journal-title":"Ter Arkh"},{"key":"10.1016\/j.ejim.2019.11.017_bib0085","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2019.05.056","article-title":"Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin","volume":"157","author":"Moayyedi","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2019.11.017_bib0086","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3164\/jcbn.15-1","article-title":"Long-term efficacy and safety of rabeprazole in patients taking low-dose aspirin with a history of peptic ulcers: a phase 2\/3, randomized, parallel-group, multicenter, extension clinical trial","volume":"56","author":"Fujishiro","year":"2015","journal-title":"J Clin Biochem Nutr"},{"key":"10.1016\/j.ejim.2019.11.017_bib0087","first-page":"1","article-title":"Influence of rabeprazole and famotidine on pharmacodynamic profile of dual antiplatelet therapy in clopidogrel-sensitive patients: the randomized, prospective, protect trial","author":"Ahn","year":"2019","journal-title":"Platelets"},{"key":"10.1016\/j.ejim.2019.11.017_bib0088","first-page":"1334","article-title":"Focused 2012 update of the canadian cardiovascular society guidelines for the use of antiplatelet therapy","volume":"29","author":"Tanguay","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ejim.2019.11.017_bib0089","first-page":"214","article-title":"Canadian cardiovascular society\/Canadian association of interventional cardiology focused update of the guidelines for the use of antiplatelet therapy","volume":"34","author":"Mehta","year":"2018","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ejim.2019.11.017_bib0090","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the american college of cardiology\/American heart association task force on clinical practice guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2019.11.017_bib0091","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"Valgimigli","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2019.11.017_bib0092","first-page":"354","article-title":"Deprescribing proton pump inhibitors: evidence-based clinical practice guideline","volume":"63","author":"Farrell","year":"2017","journal-title":"Can Fam Phys"},{"key":"10.1016\/j.ejim.2019.11.017_bib0093","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","article-title":"The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American gastroenterological association","volume":"152","author":"Freedberg","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2019.11.017_bib0094","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40265-017-0712-6","article-title":"The safety of appropriate use of over-the-counter proton pump inhibitors: an evidence-based review and Delphi consensus","volume":"77","author":"Johnson","year":"2017","journal-title":"Drugs"},{"key":"#cr-split#-10.1016\/j.ejim.2019.11.017_bib0095.1","unstructured":"N.H.S. Foundation Trust: Guidance for safe and effective use of proton pump inhibitors (PPIs). 2018"},{"key":"#cr-split#-10.1016\/j.ejim.2019.11.017_bib0095.2","unstructured":"http:\/\/www.barnsleyccg.nhs.uk\/CCG%20Downloads\/Members\/Medicines%20management\/Area%20prescribing%20committee\/201803-04%20-%20APC%20Memo%20Enclosure%20-%20Guidance%20for%20Safe%20and%20Effective%20use%20of%20Proton%20Pump%20Inhibitors%20-%20March-April%202018.pdf (accessed August 27, 2019)."},{"issue":"3","key":"10.1016\/j.ejim.2019.11.017_bib0096","doi-asserted-by":"crossref","DOI":"10.3399\/bjgpopen19X101651","article-title":"Sustained proton pump inhibitor deprescribing among dyspeptic patients in general practice: a return to self-management through a programme of education and alginate rescue therapy. a prospective interventional study","volume":"3","author":"Coyle","year":"2019","journal-title":"BJGP Open"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620519304182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620519304182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:30:35Z","timestamp":1760607035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620519304182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":97,"alternative-id":["S0953620519304182"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2019.11.017","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proton pump inhibitors and cardiovascular adverse effects: Real or surreal worries?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2019.11.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}